Advertisement
Advertisement
Trending on PharmExec
1
Astellas Pharmaceuticals Enters $1.7 Billion Global Collaboration with Vir Biotechnology to advance PSMA-targeting PRO-XTEN
2
FDA Grants Full Approval to Braftovi Combination for First-Line BRAF V600E–Mutant Metastatic Colorectal Cancer
3
FDA Approves Dupixent as First Treatment for Allergic Fungal Rhinosinusitis in Adults and Children
4
How Does FDA's Decision Represent a Broader Regulatory Recalibration?
5